Drug Trial Radar · NCT01349049
Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Last checked: Nov 20, 2026Latest source record: Mar 2, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
90
Actual
Start
Nov 21, 2011
Primary completion
Jan 20, 2015
Study completion Jan 9, 2018
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- Collaborators
- Plexxikon
- First posted
- May 6, 2011
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety of study drug PLX3397 at 3 dose levels (800 mg/day, 1000 mg/day, and 1200 mg/day) and explore the efficacy in patients with relapsed or refractory acute myeloid leukemia (AML). Additional dose levels beyond 1200 mg/day may be considered based on safety and efficacy observations.
Conditions
- Acute Myeloid Leukemia
Interventions
PLX3397Drug
Maximum Tolerated Dose of PLX3397 will be administered orally, twice daily.
PLX3397Drug
The drug product is available in capsule form, to be taken orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Summary of Best Modified Criteria Response Results, Bridged-to-Transplant (BTT) Participants, and Composite Remission Rates in Patients on Treatment With PLX3397 (Dose Expansion, Part 2).Time frame: 1 year post dose
- Summary of Time-to-Event Endpoints in Patients on Treatment With PLX3397 (Dose Expansion, Part 2)Time frame: 1 year post dose
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
UCSF Helen Diller Family Family Comprehensive Cancer Center
San Francisco, California
Northwestern University
Chicago, Illinois
Johns Hopkins University
Baltimore, Maryland
Dana Farber Cancer Institute
Boston, Massachusetts
Roswell Park Cancer Institute
Buffalo, New York
Memorial Sloan Kettering Cancer Center
New York, New York
New York Presby Hospital, Weill Medical College at Cornell University
New York, New York
University of Pennsylvania, Abramson Cancer Center
Philadelphia, Pennsylvania
Fred Hutchinson Cancer Research Center
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.